Antimicrobial Resistance (AMR)
The WHO lists AMR in the top 10 global health threats but new antibiotic development is not keeping pace with the emergence of resistant pathogens. Novel ways to structure the market are being explored which incentivise developers and give healthcare systems new tools to fight AMR.
OHE Models Incentives for Antibiotic Drug Development
18 March 2014
The OHE model takes into account the value to society of new antibiotics as well as the risks and rewards for payers and the entities developing…
Antibacterials: Roundtable Addresses the Critical Issues
10 November 2011
Antibacterial drug resistance is a serious and growing worldwide problem that threatens our ability to cure traditionally treatable diseases and to successfully perform numerous surgical procedures…
Incentives for R&D for New Antimicrobial Drugs
31 August 2011
Just published by OHE researchers is a comprehensive analysis of what policy measures are needed to counter the growing global problem of antimicrobial resistance. Their key…
News Release: Fighting Superbugs
6 July 2011
A new report today by the Office of Health Economics (OHE) called for a shake up in the way future antibiotics are to be rewarded in…
New: Antimicrobial Drug Incentives
6 April 2011
Antimicrobial resistance (AMR) is becoming a major global public health threat. In this new OHE Research Paper, the authors identify barriers to the development of new…
Summary Report of the OHE/EFPIA Antibacterial Roundtable
1 November 2011
Antibacterial drug resistance is a serious and growing worldwide problem that threatens our ability to cure traditionally treatable diseases and to successfully perform numerous surgical procedures…
Incentives for R&D for New Antimicrobial Drugs
1 April 2011
Antimicrobial resistance (AMR) is becoming a major global public health threat and has begun to command attention from European and US policy makers. An initial focus…
New Drugs to Tackle Antimicrobial Resistance: Analysis of EU Policy Options
1 April 2011
Antimicrobial resistance (AMR) to drugs is a natural and unavoidable consequence of treating infectious diseases. A growing global public health threat, AMR reduces the chances of…
New Antimicrobial Drugs: EU Policy Options
4 October 2010
Antimicrobial resistance to drugs is a growing global public health issue. The EU began a discussion in 2009 about which policies can best encourage the development…